Exhaustive Study Guide: Wound Biomarkers, Multi-Omics Protocols, and Phage Therapy Cohorts

Layered Framework for Wound Biomarker Identification

  • Purpose of Biomarker Panel Establishment:

    • Establish definitive reference biomarkers to differentiate sterile tissue repair, bacterial infection mechanisms, and phage-mediated responses in wound environments.

    • Provide standardized metabolomic diagnostic panels for academic and clinical research reference.

  • Tiered Experimental Layers:

    • Sterile Wound Healing Layer: Identification of specific metabolite alterations strictly correlated with non-infected, baseline wound repair and tissue re-epithelialization.

    • Pseudomonas aeruginosa Layer: Isolation of biomarkers exclusively associated with Pseudomonas aeruginosa infection (strains PAO1 and PA1 B11).

    • Phage Presence Layer: Characterization of metabolic signatures induced solely by bacteriophage exposure on the wound bed.

    • Combined Pathogen and Phage Layer: Dissection of unique metabolic responses triggered by co-presence of Pseudomonas and bacteriophage, distinguishing pathogen-specific responses from phage-driven dynamics.

  • Publication Goal:

    • Propose a comprehensive guidelines paper detailing key metabolite panels to monitor during wound metabolomics investigations.

Extraction Method Comparison and Multi-Omics Integration

  • Methodological Benchmarking:

    • Historical Isolation Method: 7-day control pig study conducted in October/November 2022 using an earlier extraction technique (evaluated against form extractions).

    • Revised Isolation Protocol: Optimized metabolite extraction procedure developed to enhance yield, resulting in broader metabolite recovery or specific chemical class biases.

  • Transcriptomics (RNA-Seq) Strategy:

    • High financial cost necessitates strict sample prioritization before submission.

    • Submission options under evaluation:

    • Process the 2022 7-day control samples from the historical extraction protocol.

    • Process 2026 control samples from the updated isolation protocol.

    • Process both cohorts simultaneously to conduct a direct method comparison, quantifying metabolite recovery gains, losses, or structural skews.

    • RNA-seq processing turnaround time: Approximately 3 weeks post-submission.

  • Animal Model Standardization:

    • Pigs selected across studies are obtained from the same breeder, identical strain (Genetics Core or OSU Swine), and maintained under identical environmental conditions to minimize biological noise.

    • Inherent inter-animal variability remains a factor when comparing distinct historical cohorts.

Comprehensive Inventory and Classification of Experimental Pig Cohorts

  • October/November 2022 Cohort:

    • Setup: 7-day control pig experiment.

    • Application: Baseline isolation methodology and initial metabolomic benchmarking.

  • July/August 2024 Cohort:

    • Setup: 35-day experiment utilizing 3 female pigs sourced from OSU Swine facilities.

    • Conditions: Uninfected control, PAO1 infected, PAO1 + PhiKNV (FeKMV) treated, and PhiKNV (FeKMV) phage alone.

    • Application: Serves as the foundational single-phage therapy dataset.

  • October/November 2024 Cohort:

    • Setup: Pigs obtained from the Genetics Core facility.

    • Outcome: Infection failed due to spontaneous immune clearance by the animals.

    • Utility: Designated exclusively for extraction practice and training; excluded from publication datasets.

    • Financial Benchmark: Experimental cost was $20,000 per pig trial.

  • January 2025 Cohort:

    • Setup: Single pig study sourced from Cleveland Center, infected with PAO1 B11.

    • Outcome: Natural infection clearance resulting in bacterial load reduction to 104 CFU10^4\,\text{CFU} (compared to the required sustained threshold of 0.5×105 CFU0.5 \times 10^5\,\text{CFU}).

    • Utility: Restricted to technical training; excluded from primary comparative studies.

  • April 2025 Cohort:

    • Setup: Short-course experiment focused on pulmonary tissue and fluid sampling.

  • May 2025 Cohort:

    • Setup: Male burn control pig study covering timelines up to 35 days.

    • Utility: Provides an additional biological control replicate spanning day 7 to day 35.

  • June/July 2025 Cohort:

    • Setup: 35-day repetition of the single-phage experiment using OSU Swine pigs.

    • Conditions: PAO1, PAO1 + PhiKNV (FeKMV), and PhiKNV alone.

    • Utility: Primary biological replicate for the 2024 single-phage trial.

  • June 2026 Cohort:

    • Setup: Female pigs infected with a PAO1 transposon mutant library and treated with single-phage therapy.

  • June/July 2026 Cohort (Experiment #2 - 5-Pig Study):

    • Setup: 35-day experiment utilizing 5 pigs (male/female setup).

    • Conditions: Uninfected control, PAO1 infected, PAO1 + B11 phage cocktail (simultaneous), PAO1 + B11 phage cocktail (sequential administration), and phage cocktail alone on wound.

    • Utility: Evaluates wound repair kinetics, scar formation, and cocktail vs. sequential phage administration efficiency.

Multi-Omics Processing Protocols and Analytical Constraints

  • Fractionation and Multi-Omics Extraction:

    • Simultaneous harvesting of Metabolomics, Lipidomics, and Proteomics fractions from collected tissue samples.

    • Sample yield per animal: 2024 cohort yielded 3 stored fractions per animal; 2026 cohort yielded 6 stored fractions per animal.

    • Metabolomics and lipidomics fractions processed internally; proteomics fractions isolated and set aside for dedicated downstream analysis.

  • Mass Spectrometry Batching Rules:

    • Direct comparative analysis across cohorts (e.g., single phage vs. simultaneous cocktail vs. sequential cocktail) requires all target samples to be prepared and analyzed within a single mass spectrometry instrument run to eliminate inter-run batch effects.

    • Processing Priority: Process July/August 2024 single-phage samples and June/July 2026 5-pig samples together in a single mass spectrometry batch before processing female transposon library samples.

  • Total Sample Volume:

    • Cumulative multi-omics workload exceeds 200 individual samples across all active 35-day experimental cohorts.

Respiratory vs. Cutaneous Biomarker Profiles

  • Anatomical Differences in Metabolite Profiles:

    • Cutaneous wound biomarker profiles do not directly correspond to respiratory tract signatures (nasal cavity, bronchial tissue, and lung parenchyma).

    • A distinct, specialized reference spreadsheet is required for pulmonary metabolite analysis.

  • Grant Application Requirements:

    • Pulmonary biomarker evaluation forms key preliminary data for a grant application targeted for submission in February.

Strategic Action Plan and Analytical Priorities

  • Priority 1: Methodology and Transcriptomics Decisions:

    • Finalize control pig cohort selection for the methodology paper (evaluating 2022 7-day, May 2025, or 2026 controls).

    • Select target tissue samples for RNA-seq (transcriptomics) submission.

    • Select target sample sets for metagenomics (metaG) analysis.

  • Priority 2: Cutaneous Biomarker Screening:

    • Map key metabolite panels across completed skin datasets to establish baseline healing, PAO1 infection, single-phage, and cocktail-phage signatures.

  • Priority 3a: Multi-Omics Sample Processing:

    • Co-extract and run multi-omics fractions (metabolomics, lipidomics, proteomics) for 2024 single-phage samples and June/July 2026 5-pig samples in a unified mass spectrometry run.

  • Priority 3b: Pulmonary Biomarker Screening:

    • Analyze pulmonary mass spectrometry datasets against respiratory biomarker panels to compile preliminary figures for the February grant deadline.


Layered Framework for Wound Biomarker Identification
  • Purpose of Biomarker Panel Establishment:

    • Establish definitive, standardized reference biomarkers to differentiate sterile tissue repair, bacterial infection mechanisms, and phage-mediated dynamics in wound environments.

    • Provide standardized metabolomic diagnostic panels for academic and clinical research reference, featuring dedicated manuscript sections for each analytical layer.

  • Tiered Experimental Layers:

    • Sterile Wound Healing Layer: Identification of specific metabolite alterations strictly correlated with non-infected, baseline wound repair and tissue re-epithelialization across timelines ranging from day 77 to day 3535.

    • Pseudomonas aeruginosa Layer: Isolation of biomarkers exclusively associated with Pseudomonas aeruginosa infection (strains PAO1 and PA1 B11).

    • Phage Presence Layer: Characterization of metabolic signatures induced solely by bacteriophage exposure (such as PhiKNV / FeKMV) on the wound bed without bacterial infection.

    • Combined Pathogen and Phage Layer: Dissection of unique metabolic responses triggered by the co-presence of Pseudomonas and bacteriophage, distinguishing pathogen-specific responses from phage-driven dynamics (including single phage vs. simultaneous cocktail vs. sequential cocktail administration).

  • Publication Goal:

    • Propose a comprehensive guidelines paper detailing key metabolite panels to monitor during wound metabolomics investigations, providing explicit reference sections for sterile healing, infection, phage treatment, and combined therapies.

Extraction Method Comparison and Multi-Omics Integration
  • Methodological Benchmarking:

    • Historical Isolation Method: 7-day control pig study conducted in October/November 2022 using an earlier extraction technique (developed by Yani) evaluated against form extractions.

    • Revised Isolation Protocol: Optimized metabolite extraction procedure developed with Malak to enhance overall metabolite yield, broaden recovery, or evaluate chemical class biases.

  • Transcriptomics (RNA-Seq) Strategy:

    • High financial cost requires strict sample prioritization prior to submission.

    • Submission options under evaluation:

    • Process the 2022 7-day control samples from the historical extraction protocol.

    • Process 2026 control samples from the updated isolation protocol.

    • Process both cohorts simultaneously to conduct a direct method comparison, quantifying metabolite recovery gains, losses, or structural skews.

    • RNA-seq processing turnaround time: Approximately 3 weeks3\,\text{weeks} post-submission.

  • Animal Model Standardization:

    • Pigs selected across studies are obtained from the same breeder, identical strain (Genetics Core or OSU Swine), and maintained under identical environmental conditions to minimize biological noise.

    • Inherent inter-animal variability remains a factor when comparing distinct historical cohorts.

Comprehensive Inventory and Classification of Experimental Pig Cohorts
  • October/November 2022 Cohort:

    • Setup: 7-day control pig experiment conducted by Yani.

    • Application: Baseline isolation methodology and initial metabolomic benchmarking.

  • July/August 2024 Cohort:

    • Setup: 35-day experiment utilizing 33 female pigs sourced from OSU Swine facilities.

    • Conditions: PAO1 infected, PAO1 + PhiKNV (FeKMV) treated, and PhiKNV (FeKMV) phage alone (lacked an uninfected control).

    • Application: Serves as the foundational single-phage therapy dataset.

  • October/November 2024 Cohort:

    • Setup: Pigs obtained from the Genetics Core facility.

    • Outcome: Infection failed due to spontaneous immune clearance by the animals.

    • Utility: Designated exclusively for extraction practice and training; excluded from publication datasets.

    • Financial Benchmark: Experimental cost was $20,000\$20,000 per pig trial.

  • January 2025 Cohort:

    • Setup: Single pig study sourced from Cleveland Center, infected with PAO1 B11.

    • Outcome: Natural infection clearance resulting in bacterial load reduction to 104 CFU10^4\,\text{CFU} (compared to the required sustained threshold of 0.5×105 CFU0.5 \times 10^5\,\text{CFU}).

    • Utility: Restricted to technical training; excluded from primary comparative studies.

  • April 2025 Cohort:

    • Setup: Short-course experiment focused on pulmonary tissue and fluid sampling.

  • May 2025 Cohort:

    • Setup: Male burn control pig study covering timelines up to 35 days35\,\text{days}.

    • Utility: Provides an additional biological control replicate spanning day 77 to day 3535.

  • June/July 2025 Cohort:

    • Setup: 35-day repetition of the single-phage experiment using OSU Swine pigs.

    • Conditions: PAO1, PAO1 + PhiKNV (FeKMV), and PhiKNV alone.

    • Utility: Primary biological replicate for the 2024 single-phage trial.

  • June 2026 Cohort:

    • Setup: Female pigs infected with a PAO1 transposon mutant library and treated with single-phage therapy.

  • June/July 2026 Cohort (Experiment #2 - 5-Pig Study):

    • Setup: 35-day experiment utilizing 55 pigs (male/female setup).

    • Conditions: Uninfected control, PAO1 infected, PAO1 + B11 phage cocktail (simultaneous), PAO1 + B11 phage cocktail (sequential administration), and phage cocktail alone on wound.

    • Utility: Evaluates wound repair kinetics, scar formation, and cocktail vs. sequential phage administration efficiency.

Multi-Omics Processing Protocols and Analytical Constraints
  • Fractionation and Multi-Omics Extraction:

    • Simultaneous harvesting of Metabolomics, Lipidomics, and Proteomics fractions from collected tissue samples.

    • Sample yield per animal: 2024 cohort yielded 33 stored fractions per animal; 2026 cohort yielded 66 stored fractions per animal.

    • Metabolomics and lipidomics fractions processed internally; proteomics fractions isolated and set aside for dedicated downstream analysis.

  • Mass Spectrometry Batching Rules:

    • Direct comparative analysis across cohorts (e.g., single phage vs. simultaneous cocktail vs. sequential cocktail) requires all target samples to be prepared and analyzed within a single mass spectrometry instrument run to eliminate inter-run batch effects.

    • Processing Priority: Process July/August 2024 single-phage samples and June/July 2026 5-pig samples together in a single mass spectrometry batch before processing female transposon library samples.

  • Total Sample Volume:

    • Cumulative multi-omics workload exceeds 200200 individual samples across all active 35-day experimental cohorts.

Respiratory vs. Cutaneous Biomarker Profiles
  • Anatomical Differences in Metabolite Profiles:

    • Cutaneous wound biomarker profiles do not directly correspond to respiratory tract signatures (nasal cavity, bronchial tissue, and lung parenchyma).

    • A distinct, specialized reference spreadsheet is required for pulmonary metabolite analysis.

  • Grant Application Requirements:

    • Pulmonary biomarker evaluation forms key preliminary data for a grant application targeted for submission in February.

Strategic Action Plan and Analytical Priorities
  • Priority 1: Methodology and Transcriptomics Decisions:

    • Finalize control pig cohort selection for the methodology paper (evaluating 2022 7-day, May 2025, or 2026 controls).

    • Select target tissue samples for RNA-seq (transcriptomics) submission (3 week3\,\text{week} turnaround time).

    • Select target sample sets for metagenomics (metaG) analysis in coordination with James.

  • Priority 2: Cutaneous Biomarker Screening:

    • Map key metabolite panels across completed skin datasets to establish baseline healing, PAO1 infection, single-phage, and cocktail-phage signatures.

  • Priority 3a: Multi-Omics Sample Processing:

    • Co-extract and run multi-omics fractions (metabolomics, lipidomics, proteomics) for 2024 single-phage samples and June/July 2026 5-pig samples in a unified mass spectrometry run.

  • Priority 3b: Pulmonary Biomarker Screening:

    • Analyze pulmonary mass spectrometry datasets against respiratory biomarker panels to compile preliminary figures for the February grant deadline.